Non-integrating Viral Vector for Pluripotent Stem Cell Production

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Conventional methods for producing induced pluripotent stem cells using retroviral vectors integrate foreign genes into the chromosomes, leading to chromosomal abnormalities, cancer risks, and heterogeneity issues, complicating their use in treatments and studies.

Innovation Solution

The use of chromosomally non-integrating viral vectors, such as RNA viral vectors like Sendai virus vectors, to introduce nuclear reprogramming factors without integrating into the host chromosomes, ensuring the production of pluripotent stem cells that are genetically homogeneous and free from cancer risks.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Productivity

If retroviral vectors are used to introduce reprogramming factors, then gene introduction efficiency is improved, but chromosomal integration causes safety risks and heterogeneity

Engineering Contradiction:

Improvegene introduction efficiencyVSAvoidsafety and genetic homogeneity

Core Design Contradiction:

ProductivityVSReliability

Solution Approach 1:

The patent extracts the harmful integration function from the viral vector system by using adenoviral vectors that deliberately avoid chromosomal integration. The vector delivers reprogramming factors transiently without integrating into host DNA, thereby removing the safety risks and heterogeneity problems associated with retroviral integration while maintaining gene delivery capability

Inventive Principle:

Principle #2Taking out (Extraction)

Solution Approach 2:

The patent uses an intermediary approach by employing adenoviral vectors as a temporary delivery vehicle that does not permanently integrate. The vector serves as a mediator to introduce reprogramming factors, which are then expressed transiently to induce pluripotency without leaving permanent genetic modifications in the host genome

Inventive Principle:

Principle #24Intermediary (Mediator)

2Stability of the object's composition

If chromosomally integrating vectors are used, then stable gene expression is achieved, but chromosomal abnormalities and cancer risks increase

Engineering Contradiction:

Improvegene expression stabilityVSAvoidchromosomal abnormalities and cancer risk

Core Design Contradiction:

Stability of the object's compositionVSObject-affected harmful factors

Solution Approach 1:

The patent removes the integration step entirely from the gene delivery process by using adenoviral vectors that replicate in the nucleus without integrating into host chromosomes. This extraction of the integration function eliminates chromosomal abnormalities and cancer risks while the vectors maintain sufficient gene expression stability to induce pluripotency

Inventive Principle:

Principle #2Taking out (Extraction)

Solution Approach 2:

The patent employs disposable, non-integrating viral vectors that perform their delivery function temporarily and then are eliminated. The adenoviral vectors serve as short-lived delivery vehicles that complete their purpose of introducing reprogramming factors without permanently altering host genetics, thereby avoiding long-term safety issues

Inventive Principle:

Principle #27Cheap short-living objects (Disposable)

3Productivity

If multiple viral vectors are used to introduce reprogramming factors, then reprogramming efficiency is improved, but vector complexity and potential for integration increase

Engineering Contradiction:

Improvereprogramming efficiencyVSAvoidvector system complexity

Core Design Contradiction:

ProductivityVSDevice complexity

Solution Approach 1:

The patent combines multiple reprogramming factor delivery into a unified adenoviral vector system. By using adenoviral vectors that can carry multiple transgenes or using coordinated transduction with controlled multiplicity of infection, the patent achieves efficient reprogramming while maintaining a relatively simple non-integrating vector architecture

Inventive Principle:

Principle #5Merging (Combining)

Data Source

PatentUS11136594B2Method for production of reprogrammed cell using chromosomally unintegrated virus vector

Publication Date: 2021.10.05 ID PHARMA

AI summary

An objective of the present invention is to provide vectors for conveniently and efficiently producing ES-like cells in which foreign genes are not integrated into the chromosome. The present inventors discovered methods for producing ES-like cells from somatic cells using chromosomally non-integrating viral vectors. Since no foreign gene is integrated into the chromosome of the produced ES-like cells, they are advantageous in tests and research, and immunological rejection and ethical problems can be avoided in disease treatments.